206 related articles for article (PubMed ID: 33548073)
1. Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
Kim EJ; Yoo C; Kang HJ; Kim KP; Ryu MH; Park SR; Lee D; Choi J; Shim JH; Kim KM; Lim YS; Lee HC; Ryoo BY
Liver Int; 2021 Jun; 41(6):1398-1408. PubMed ID: 33548073
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
Jang YJ; Kim EJ; Kim HD; Kim KP; Ryu MH; Park SR; Choi WM; Lee D; Choi J; Shim JH; Kim KM; Lim YS; Lee HC; Ryoo BY; Yoo C
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7547-7555. PubMed ID: 36971796
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma-a European multicenter cohort.
Pomej K; Balcar L; Shmanko K; Welland S; Himmelsbach V; Scheiner B; Mahyera A; Mozayani B; Trauner M; Finkelmeier F; Weinmann A; Vogel A; Pinter M
ESMO Open; 2023 Feb; 8(1):100783. PubMed ID: 36753993
[TBL] [Abstract][Full Text] [Related]
4. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
Kobayashi S; Terashima T; Shiba S; Yoshida Y; Yamada I; Iwadou S; Horiguchi S; Takahashi H; Suzuki E; Moriguchi M; Tsuji K; Otsuka T; Asagi A; Kojima Y; Takada R; Morizane C; Mizuno N; Ikeda M; Ueno M; Furuse J
Cancer Sci; 2018 Aug; 109(8):2549-2557. PubMed ID: 29856900
[TBL] [Abstract][Full Text] [Related]
5. Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.
Gigante E; Hobeika C; Le Bail B; Paradis V; Tougeron D; Lequoy M; Bouattour M; Blanc JF; Ganne-Carrié N; Tran H; Hollande C; Allaire M; Amaddeo G; Regnault H; Vigneron P; Ronot M; Elkrief L; Verset G; Trepo E; Zaanan A; Ziol M; Ningarhari M; Calderaro J; Edeline J; Nault JC
Liver Cancer; 2022 Sep; 11(5):460-473. PubMed ID: 36158591
[TBL] [Abstract][Full Text] [Related]
6. Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study.
Gigante E; Bouattour M; Bedoya JU; Regnault H; Ziol M; Assenat E; Paradis V; Calderaro J; Ganne-Carrié N; Bouhier-Leporrier K; Amaddeo G; Nault JC
United European Gastroenterol J; 2024 May; 12(4):429-439. PubMed ID: 38059651
[TBL] [Abstract][Full Text] [Related]
7. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
[TBL] [Abstract][Full Text] [Related]
8. Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis.
Zhou C; Wang Y; Ma L; Qian X; Yang C; Zeng M
Eur Radiol; 2022 Jan; 32(1):78-88. PubMed ID: 34279688
[TBL] [Abstract][Full Text] [Related]
9. Post-resection prognosis of combined hepatocellular carcinoma-cholangiocarcinoma cannot be predicted by the 2019 World Health Organization classification.
Kim M; Hwang S; Ahn CS; Kim KH; Moon DB; Song GW; Jung DH; Hong SM
Asian J Surg; 2021 Nov; 44(11):1389-1395. PubMed ID: 33766528
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study.
Salimon M; Prieux-Klotz C; Tougeron D; Hautefeuille V; Caulet M; Gournay J; Matysiak-Budnik T; Bennouna J; Tiako Meyo M; Lecomte T; Zaanan A; Touchefeu Y
Br J Cancer; 2018 Feb; 118(3):325-330. PubMed ID: 29169182
[TBL] [Abstract][Full Text] [Related]
11. Prognostic analysis of patients with combined hepatocellular-cholangiocarcinoma after radical resection: A retrospective multicenter cohort study.
Zhang G; Chen BW; Yang XB; Wang HY; Yang X; Xie FC; Chen XQ; Yu LX; Shi J; Lu YY; Zhao HT
World J Gastroenterol; 2022 Nov; 28(41):5968-5981. PubMed ID: 36405111
[TBL] [Abstract][Full Text] [Related]
12. Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study.
Liguori C; Copparoni C; Felicetti C; Pecci F; Lupi A; Pinterpe G; Berardi R; Giampieri R
Curr Oncol; 2023 Jan; 30(1):1032-1045. PubMed ID: 36661728
[TBL] [Abstract][Full Text] [Related]
13. Combined Hepatocellular-Cholangiocarcinoma: Magnetic Resonance Imaging Features and Prognosis According to Risk Factors for Hepatocellular Carcinoma.
Kim DH; Choi SH; Kim DW; Lee SS; Lim YS; Kim SY; Kim HJ; Kim JH; Byun JH
J Magn Reson Imaging; 2021 Jun; 53(6):1803-1812. PubMed ID: 33565208
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of the efficacy and safety of hepatic arterial infusion chemotherapy for unresectable hepatitis B-related intrahepatic cholangiocarcinoma].
He MR; Zheng ZK; Wu TQ; Chen MS; Zhou ZG
Zhonghua Wai Ke Za Zhi; 2024 Apr; 62(4):309-315. PubMed ID: 38432672
[No Abstract] [Full Text] [Related]
15. Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion.
Tanaka T; Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
Oncology; 2020; 98(9):621-629. PubMed ID: 32434180
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis.
Lin CW; Wu TC; Lin HY; Hung CM; Hsieh PM; Yeh JH; Hsiao P; Huang YL; Li YC; Wang YC; Shu CW; Chen YS
BMC Gastroenterol; 2021 Jan; 21(1):20. PubMed ID: 33413162
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma.
Zhang N; Yu BR; Wang YX; Zhao YM; Zhou JM; Wang M; Wang LR; Lin ZH; Zhang T; Wang L
J Dig Dis; 2022 Aug; 23(8-9):535-545. PubMed ID: 36148493
[TBL] [Abstract][Full Text] [Related]
18. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival.
Marquardt S; Kirstein MM; Brüning R; Zeile M; Ferrucci PF; Prevoo W; Radeleff B; Trillaud H; Tselikas L; Vicente E; Wiggermann P; Manns MP; Vogel A; Wacker FK
Eur Radiol; 2019 Apr; 29(4):1882-1892. PubMed ID: 30255257
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
Zhu C; Li H; Yang X; Wang S; Wang Y; Zhang N; Wang Y; Xue J; Zhang L; Ning C; Yang X; Xun Z; Chao J; Long J; Sang X; Zhu Z; Zhao H
Cancer Immunol Immunother; 2023 Sep; 72(9):2949-2960. PubMed ID: 37247023
[TBL] [Abstract][Full Text] [Related]
20. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?
Wang X; Wang W; Ma X; Lu X; Li S; Zeng M; Xu K; Yang C
Eur Radiol; 2020 Oct; 30(10):5337-5347. PubMed ID: 32385649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]